AstraZeneca PLC has a new near-term commercial opportunity in asthma with PT027, a fixed-dose combination of albuterol and budesonide, that the company believes could be used across the spectrum of patients with mild to severe asthma. The company, with its development partner Avillion LLP, released positive data from two Phase III trials testing the combination on 9 September and said the data support a regulatory filing in 2022.
"The opportunity is across all spectrums of asthma, all 25 million patients
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?